Evidence map›Paper›PMID 25218890›Full record

ArticleVirchows Archiv : an international journal of pathology2014

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.

Christopher Poremba, Jennifer Uhlendorff, Berit M Pfitzner, Guido Hennig, Kerstin Bohmann, Hans Bojar, Veit Krenn, Jan C Brase, Franziska Haufe, Manuela Averdick and 3 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03503799 active not recruitingnot on this mapstarted 2018, after this paper: background citation

Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study

Typeobservational_patient_registrySponsorNorth Eastern German Society of Gynaecological OncologyRan2018 to 2032Enrolled1,191ConditionsPrimary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, Human Epidermal Growth Factor Receptor 2 Negative TumorArmsObservation
NCT07379918 recruitingnot on this mapstarted 2026, after this paper: background citation

French Prospective Real-life Evaluation of the Endopredict® Genomic Signature for HR-positive,HER2-negative Early Breast Cancer

Typeobservational_patient_registrySponsorAssistance Publique - Hôpitaux de ParisRan2026 to 2031Enrolled1,000ConditionsBreast Cancer (Early Breast Cancer), Breast Cancer Survivors, Breast Cancer Prognostic, Early Hormone Receptor-positive (HR-positive)ArmsEndopredict test
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Use of Automated BaseScope Assay on the Leica BOND RX.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Cold Ischemia Score: An mRNA Assay for the Detection of Extended Cold Ischemia in Formalin-Fixed, Paraffin-Embedded Tissue.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2019
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christopher PorembaInstitute of Pathology Munich-North, Ernst-Platz-Straße 2, 80992, Munich, Germany, poremba@pathologie-muenchen.de.
Jennifer Uhlendorff
Berit M Pfitzner
Guido Hennig
Kerstin Bohmann
Hans Bojar
Veit Krenn
Jan C Brase
Franziska Haufe
Manuela Averdick
Manfred Dietel
Ralf Kronenwett
Carsten Denkert

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prognostic multigene expression assays have become widely available to provide additional information to standard clinical parameters and to support clinicians in treatment decisions. In this study, we analyzed the impact of variations in tissue handling on the diagnostic EndoPredict test results. EndoPredict is a quantitative reverse transcription PCR assay conducted on RNA from formalin-fixed, paraffin-embedded (FFPE) tissue that predicts the likelihood of distant recurrence in patients with ER-positive/HER2-negative breast cancer. In this study, we performed a total of 138 EndoPredict assays to study the effects of preanalytical variables such as time to fixation, fixation time, tumor cell content, and section storage time on the EndoPredict test results. A time to fixation of up to 12 h and fixation of up to 5 days did not affect the results of the gene expression test. Paired samples of FFPE sections with tumor cell content ranging from 15 to 95 % and tumor-enriched samples showed a correlation coefficient of 0.97. Test results of tissue sections that have been stored for 12 months at +4 or +20 °C showed a correlation of 0.99 when compared to results of nonstored sections. In conclusion, preanalytical tissue handling is not a critical factor for diagnostic gene expression analysis with the EndoPredict assay. The test can therefore be easily integrated into the standard workflow of molecular pathology.

Indexed as

Specimen HandlingBreast NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansParaffin EmbeddingPathology, MolecularReverse Transcriptase Polymerase Chain ReactionRNATime FactorsTissue FixationRNA

Identifiers

PMID25218890
PMCPMC4180906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.